Top-Rated Charity
Website
View similar charities
Ratings & Metrics
Joint Costs
Leukemia & Lymphoma Society's rating was adjusted for Joint Costs. If you are a donor who considers direct mail, telemarketing, and other Joint Cost solicitations to be true charitable programs, the below efficiency ratios, which were not adjusted for joint costs, may better reflect your goals.
| Program % | Cost to Raise $100 |
|---|---|
| 79% | $12 |
Accounting rules allow charities to report some telemarketing, direct mail, and other solicitation costs as Program expenses. CharityWatch believes that most donors do not consider a charity's solicitation activities to be the Programs they are intending to support with their donations. We therefore adjust such expenses out of a charity's reported Program expense and add it to Fundraising expense prior to calculating its rating.
Financial Documents
| Entity | Document Type | Tax ID |
|---|---|---|
| The Leukemia & Lymphoma Society | IRS Form 990 | 13-5644916 |
| The Leukemia & Lymphoma Society | Consolidated Audited Financial Statements | Multiple |
|
Entity: The Leukemia & Lymphoma Society Document Type: IRS Form 990 Tax ID: 13-5644916 |
|
Entity: The Leukemia & Lymphoma Society Document Type: Consolidated Audited Financial Statements Tax ID: Multiple |
Governance & Transparency
CharityWatch evaluates certain criteria related to a charity's Governance and Transparency. Donors may want to consider a charity's willingness to be open and transparent with CharityWatch to be a good litmus test for determining its commitment to public accountability.
Top Salaries
| Name | Title | Compensation | |
|---|---|---|---|
| 1 | Louis J. Degennaro | President/CEO | $623,559 |
| 2 | Mark Roithmayr | Past Executive VP/Chief Relationship Officer | $451,090 |
| 3 | Rosemarie A. Loffredo | Executive VP/CFO | $415,910 |
|
1 Name: Louis J. Degennaro Title: President/CEO Compensation: $623,559 |
|
2 Name: Mark Roithmayr Title: Past Executive VP/Chief Relationship Officer Compensation: $451,090 |
|
3 Name: Rosemarie A. Loffredo Title: Executive VP/CFO Compensation: $415,910 |
Analysts' Notes
CharityWatch Analysts perform an in-depth analysis of charities' audited financial statements and IRS tax filings, and often review other documents such as state filings, annual reports, and fundraising contracts during their evaluations. Below are select notes that CharityWatch believes may be of interest to donors.
| CharityWatch's rating of Leukemia & Lymphoma Society (LLS) is based The Leukemia & Lymphoma Society audited consolidated financial statements for the fiscal year-ended 6/30/2017. According to The Leukemia & Lymphoma Society fiscal 2017 consolidated audit (Note 1(B), Principles of Consolidation): "The accompanying [audited] consolidated financial statements include the accounts of LLS that encompass the National Office of LLS and its fifty-six chapters in the United States, and LLS's not-for-profit affiliates, including The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), The Leukemia & Lymphoma Society Research Foundation (LLSRF), Beat AML LLC (BAML) and PearlPoint Cancer Support, Inc. (PPCS). ... All significant inter-company and intra-LLS accounts and transactions have been eliminated in consolidation." |
| According to The Leukemia & Lymphoma Society (LLS) consolidated audit of June 30, 2017 (Note 7, Donated Goods, Services and Media), LLS received "donated goods, donated services for family support group facilitators and research grant reviewers, as well as donated media" on which it placed a total value of approximately $14.6 million in fiscal 2017. The value of the donated media constituted approximately $8.6 million of the total. [Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.] |
| According to The Leukemia & Lymphoma Society (LLS) consolidated audit of June 30, 2017 (Note 8, Fixed Assets, Net) [$s in thousands, as noted]: "In 2017, an impairment of fixed assets of $5,434 [thousand] was recorded for the write-off [of] a fund-raising platform that will no longer be utilized by LLS." |
| According to The Leukemia & Lymphoma Society (LLS) tax filing for the fiscal year ended June 30, 2017 re: Compensation Information, LLS reports paying severance in the amounts of $220,328, $125,350, and $111,126 to Paulette Damiano, Michele Przypyszny, and George J. Omiros, respectively, in the calendar year 2016 (IRS Form 990, Schedule J, Part III). Paulette Damiano is reported as "VP Org Dev & Change," term 6/30/2016, with total compensation of $339,547. Michele Przypyszny is reported as "Executive Director," term 7/21/2016, with total compensation of $258,685. George J. Omiros is reported as "EVP-Chief Camp&Field," term April 2015, with total compensation of $111,126. The reported total compensation amounts include the respective severance payments noted above and are for the calendar year 2016 (IRS Form 990, Schedule J, Part II). LLS also reports re: Compensation Information: "Bonuses were paid based on the achievement of the employee individual performance. Bonuses were capped according to LLS's policy..." (IRS Form 990, Schedule J, Part III). For Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees compensated more than $100,000 in 2016, LLS reports paying seven individuals "Bonus & incentive compensation." Four individuals were paid "Bonus & incentive compensation" in amounts that ranged from $11,068 to $19,082. In addition, "Bonus & incentive compensation" in the amount of $51,000, $36,593, and $32,500 was paid to Rosemarie A. Loffredo (EVP - CFO), Mark Roithmayer (EVP Chief Rel Office, term 12/31/2016), and Andrew S. Coccari (EVP Chief Prod Office), respectively. The reported total compensation in 2016 for R. Loffredo, M. Roithmayer, and A. Coccari was $415,910, $451,090, and $383,874, respectively, including the bonus payments (IRS Form 990, Schedule J, Part II). |